Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

December 31, 2011

Conditions
Dry Eye SyndromeDry Eye
Interventions
DRUG

Thymosin beta 4

A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.

DRUG

Placebo

A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.

All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

ReGenTree, LLC

INDUSTRY

NCT01387347 - Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye | Biotech Hunter | Biotech Hunter